EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieKohortenstudieOpen Access · CC BY 4.0

Patient‐Perceived Benefits of Named‐Patient Product Sublingual Immunotherapy in Allergic Rhinitis and Asthma: Primary Results From the ERAPP Real‐World Cohort Study

Davide Caimmi iD, Abdelilah Abouelfath, Régis Lassalle, Séverine Lignot-Maleyran, Emmanuelle Bignon, Patrick Blin, Evangéline Clark iD, Julien Cottet, Laure Carcaillon-Bentata, Pascal Demoly iD

Allergy · 2026

DOI: 10.1111/all.70270 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Allergy, 2026. Verfasst von Davide Caimmi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Allergy Unit, Hôpital Arnaud De Villeneuve, University Hospital of Montpellier, Montpellier, Occitanie, France. Hauptthemen laut MEDLINE: Asthma, Sublingual Immunotherapy, Rhinitis, Allergic. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Société Française d'Allergologie (SFA), Université de Bordeaux.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Named‐patient product sublingual immunotherapy (NPP‐SLIT) is widely used in France, yet real‐world evidence on patient‐perceived benefit remains limited.

Objective

To assess treatment expectations and patient‐perceived benefit over 12–15 months among recent NPP‐SLIT initiators using the Patient Benefit Index (PBI) and validated patient‐reported outcome measures (PROMs).

Methods

ERAPP is a prospective, multicenter, observational study in children and adults with IgE‐mediated respiratory allergy. Initiators (≤ 6 months on NPP‐SLIT at baseline) completed digital PROMs at baseline, Month 6, and Month 12–15. The primary endpoint was the proportion with PBI ≥ 1 at Months 12–15. Secondary endpoints were changes in PROMs; exploratory analyses examined higher PBI thresholds and item‐level fulfillment.

Results

Of 9439 enrolled, 4794 were initiators (950 children; 3844 adolescents/adults). At Month 12–15, PBI ≥ 1 was achieved by 83.8% of children and 84.0% of adolescents/adults. Symptom burden (T5SS) and rhinitis severity (ARIA) improved beyond published MIDs. Asthma control (ACT) improved, whereas changes in rhinitis control (ARCT, ≥ 12 years) and daytime sleepiness (ESS, adults) were below their respective MIDs. Treatment satisfaction (ESPIA‐Q11) increased, while adherence (GIRERD) decreased from baseline to follow‐up. Nearly half reached PBI ≥ 2 and about one‐fifth PBI ≥ 3. Item‐level analyses showed highest fulfillment for nasal obstruction relief, improved sleep, and overall symptom relief; fatigue, mood, and social aspects were less frequently fulfilled. Children generally reported slightly higher fulfillment than adolescents/adults.

Conclusion

NPP‐SLIT provides sustained, clinically meaningful benefit from the patient's perspective in both age groups. ERAPP supports the PBI as a complementary endpoint that links patient expectations to outcomes and informs patient‐centered allergy care.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AsthmaSublingual ImmunotherapyRhinitis, AllergicHumansChildFemaleAdolescentMaleAdultTreatment OutcomePatient Reported Outcome MeasuresYoung AdultChild, PreschoolProspective StudiesSymptom BurdenMiddle AgedCohort Studies

Stichwörter der Autor:innen

NPPPROMspatient's benefitquestionnairessublingual allergen immunotherapy

Autor:innen und Institutionen

  • Allergy Unit, Hôpital Arnaud De Villeneuve, University Hospital of Montpellier, Montpellier, Occitanie, France.
  • IDESP, UMR 1318, University of Montpellier - INSERM, Montpellier, Occitanie, France.
  • Bordeaux Pharmaco Epi, INSERM CIC-P 1401, Université De Bordeaux, Bordeaux, France.
  • Allergy Unit, Hospital of Mont De Marsan, Mont-de-Marsan, Nouvelle-Aquitaine, France.
  • Private Allergy Practice, Chartres, France.
  • INRIA PreMediCal, Montpellier, France.

ORCID-Profile: Davide Caimmi, Evangéline Clark, Pascal Demoly

Förderung

  • Société Française d'Allergologie (SFA)
  • Université de Bordeaux

Zitieren

APA

Caimmi, D., Abouelfath, A., Lassalle, R., Lignot-Maleyran, S., Bignon, E., Blin, P., Clark, E., Cottet, J., Carcaillon-Bentata, L., & Demoly, P. (2026). Patient‐Perceived Benefits of Named‐Patient Product Sublingual Immunotherapy in Allergic Rhinitis and Asthma: Primary Results From the ERAPP Real‐World Cohort Study. Allergy. https://doi.org/10.1111/all.70270

Vancouver

Caimmi D, Abouelfath A, Lassalle R, Lignot-Maleyran S, Bignon E, Blin P, et al. Patient‐Perceived Benefits of Named‐Patient Product Sublingual Immunotherapy in Allergic Rhinitis and Asthma: Primary Results From the ERAPP Real‐World Cohort Study. Allergy. 2026. doi:10.1111/all.70270

BibTeX
@article{Caimmi2026,
  author = {Caimmi, Davide and Abouelfath, Abdelilah and Lassalle, Régis and Lignot-Maleyran, Séverine and Bignon, Emmanuelle and Blin, Patrick and Clark, Evangéline and Cottet, Julien and Carcaillon-Bentata, Laure and Demoly, Pascal},
  title = {Patient‐Perceived Benefits of Named‐Patient Product Sublingual Immunotherapy in Allergic Rhinitis and Asthma: Primary Results From the ERAPP Real‐World Cohort Study},
  journal = {Allergy},
  year = {2026},
  doi = {10.1111/all.70270}
}
Kostenlos starten →